PTE: Reports Manipulation to Authorities

SALT LAKE CITY, Oct. 9, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced that multiple regulatory bodies are being notified of suspected significant illegal trading in the Company's securities. Such activities appear to be in strategic coordination with the publication of misleading materials. These activities have brought damages to the Company and the Company's shareholders.


PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.